H22-hPD-L1

Export PDF

Strain Information

Cell Line

H22-Cd274em1(hPDL1)/Smoc

Cat. NO.

NM-GA01-TM01

Model Description

The endogenous mouse Cd274 gene was replaced by human CD274 gene.

Strain State

Validation of tumorigenic capacity completed

Validation Data

image.png

Fig 1. hPD-L1 expression on in vitro cultured cells of H22-hPD-L1


image.png

Fig 2. hPD-L1(BALB/c) mice were inoculated with H22-hPD-L1 subcutaneously at 1×106 cells/mouse inoculum for tumor development


image.png

Fig 3. hPD-L1 expression in tumors after in vivo growth of H22-hPD-L1 in wild type hPD-L1(BALB/c) mouse. The tumors were collected at day 11 post tumor cell inoculation.


image.png

Fig 4. hPD-L1 expression in tumors after in vivo growth of H22-hPD-L1 in wild type hPD-L1(BALB/c) mouse. The tumors were collected at day 21 post tumor cell inoculation.



Related Strain(s)

CT26-hIL13RA2
Cell Line：

CT26-hIL13RA2

Cat. NO.：NM-S24A-TM30
B16F10-hPDL1-Sirpa-KO
Cell Line：B16F10-hPDL1-Sirpa-KO
Cat. NO.：NMC-230067
MC38-hPDL1-Sirpa-KO
Cell Line：MC38-hPDL1-Sirpa-KO
Cat. NO.：NMC-230068
MC38-hCD24/hPD-L1
Cell Line：

MC38-hCD24/hPD-L1

Cat. NO.：NMC-230052
B16F10-hPDL1/Sirpa
Cell Line：

B16F10-hPDL1/Sirpa

Cat. NO.：NMC-230056

You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Milestones

Our vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.

Learn more